ArticleBreast cancer research and treatment2015
Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.
Article in Breast cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Prognostic models for breast cancer: a systematic review.BMC cancer · 2019Pooled it
- Breast cancer recurrence: socioeconomic position and general practice involvement - a nationwide cohort study in Denmark.Scandinavian journal of primary health care · 2026Article
- Belgian validation of the INFLUENCE 3.0 model predicting 5-year locoregional and contralateral breast cancer recurrence.Breast (Edinburgh, Scotland) · 2026Article
- Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.NPJ breast cancer · 2026Article
- Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires.Radiation oncology (London, England) · 2025Article
- Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance.Breast cancer research and treatment · 2025Article
- Multimodal BEHRT: transformers for multimodal electronic health records to predict breast cancer prognosis.Frontiers in oncology · 2025Article
- Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands.Clinical and translational radiation oncology · 2024Article
- Opportunities for personalised follow-up in breast cancer: the gap between daily practice and recurrence risk.Breast cancer research and treatment · 2024Article
- Article
- Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.BMC cancer · 2023Article
- Needs and preferences of breast cancer survivors regarding outcome-based shared decision-making about personalised post-treatment surveillance.Journal of cancer survivorship : research and practice · 2023Article
- Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.Breast cancer research and treatment · 2023Article
- Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis.Breast cancer research and treatment · 2023Article
- Imaging Surveillance Options for Individuals With a Personal History of Breast Cancer:AJR. American journal of roentgenology · 2022Review
- Article
- Adherence to the Dutch Breast Cancer Guidelines for Surveillance in Breast Cancer Survivors: Real-World Data from a Pooled Multicenter Analysis.The oncologist · 2022Article
- The value of time-dependent risk predictions in a screening context - a comprehensive simulation analysis validated on German cancer registry data.BMC medical research methodology · 2022Article
- Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors.Breast cancer research and treatment · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to develop and validate a time-dependent logistic regression model for prediction of locoregional recurrence (LRR) of breast cancer and a web-based nomogram for clinical decision support. Women first diagnosed with early breast cancer between 2003 and 2006 in all Dutch hospitals were selected from the Netherlands Cancer Registry (n = 37,230). In the first 5 years following primary breast cancer treatment, 950 (2.6 %) patients developed a LRR as first event. Risk factors were determined using logistic regression and the risks were calculated per year, conditional on not being diagnosed with recurrence in the previous year. Discrimination and calibration were assessed. Bootstrapping was used for internal validation. Data on primary tumours diagnosed between 2007 and 2008 in 43 Dutch hospitals were used for external validation of the performance of the nomogram (n = 12,308). The final model included the variables grade, size, multifocality, and nodal involvement of the primary tumour, and whether patients were treated with radio-, chemo- or hormone therapy. The index cohort showed an area under the ROC curve of 0.84, 0.77, 0.70, 0.73 and 0.62, respectively, per subsequent year after primary treatment. Model predictions were well calibrated. Estimates in the validation cohort did not differ significantly from the index cohort. The results were incorporated in a web-based nomogram ( http://www.utwente.nl/mira/influence ). This validated nomogram can be used as an instrument to identify patients with a low or high risk of LRR who might benefit from a less or more intensive follow-up after breast cancer and to aid clinical decision making for personalised follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.